Table 3.
Summary of thyroid cancer cell line take rates in the orthotopic and intracardiac injection metastasis models
| Tumor | Cell line | Mutation(s) | OT take rate | Tumor vol mm3 | IC take rate |
|---|---|---|---|---|---|
| ATC | 8505C | BRAF(V600E) | 100 % | 84 | 90 % |
| ATC | T238 | BRAF(V600E), PIK3CA(E542K) | 100 % | 212 | Not assessed |
| ATC | HTh74 | None knowna | 86 % | 59.5 | 100 % |
| ATC | HTh7 | NRAS(Q61R) | Not assessed | N/A | 100 % |
| ATC | THJ-16T | PIK3CA(E545K) | 75 % | 2.5 | 83 % |
| ATC | Cal62 | KRAS(G12R) | 63 % | 26.7 | 70 % |
| ATC | C643 | HRAS(G13R) | 0 % | N/A | 14 % |
| ATC | SW1736 | BRAF(V600E) | 0 % | N/A | 0 % |
| PTC | K1/GLAG-66 | BRAF(V600E), PIK3CA(E542K) | 100 % | 181 | 0 % |
| PTC | BCPAP | BRAF(V600E) | 92 % | 214 | 30 % |
| PTC | MDA-T41 | BRAF(V600E) | 0 % | N/A | Not assessed |
| PTC | TPC-1 | RET/PTC1 | 0 % | N/A | 0 % |
aNo known mutations in BRAF, NRAS, HRAS, KRAS, PIK3CA, PTEN, AKT1, and AKT2